Cellular Biomedicine Group Inc. , a biomedicine firm engaged in the development of new treatments for degenerative and cancerous diseases, today announced that Professor Zhong Chen Kou, Chief Scientist of Immunology for the Company, will present "Assay for Monitoring T Cell Clonality Response to Cancer Immunotherapy" at the 2014 China Biotherapy Conference on October 12, at 9:55 a.m. Beijing time at the Beijing National Convention Center. This annual conference takes place on October 11 and 12, 2014 and is jointly sponsored by Cellular Biomedicine Group, Chinese Medical Doctor Association, Hospital 301, Armed Police General Hospital and Chinese Biomedical Engineering Institute of Technology.
http://ift.tt/1st9Ud1
http://ift.tt/1st9Ud1
No comments:
Post a Comment